Role of type of vascular access in erythropoietin and intravenous iron requirements in haemodialysis.

This is a very interesting point that is probably unknown to many clinicians. Personally, I was not aware of this problem. These findings remain to be explained. Why should anti-platelet agents influence EPO and iron dosages? Higher iron dosages in PTFE graft patients could simply be a consequence of higher EPO dosages.

– C. Breymann.